Century Kaitai

· World's First, China's First ~ Century Kangtai Multilevel Depth-of-Field Extended EDOF Intraocular Lens Unveiled!

On July 11, at the A111 booth of Century Kangle in the 25th Chinese Medical Association Cataract and Refractive Surgery Academic Conference (CSCRS 2025), a highlight moment was reached –World's First Multi-Level Extended Depth of Focus Intraocular Lens, China's First EDOF Innovative DeviceGlory Released!

· LuminVue® Trifocal Plus Ignites Academic Frenzy!

Recently, at the 25th Chinese Medical Association Cataract and Refractive Surgery Academic Conference (CSCRS2025), Century KANGTAI's "Crystal Brilliance Intelligence Gathering, Visionary New Chapter" series of academic activities attracted significant attention in the industry. Among them,"Radiant Spectrum, Enlightening New Vision" Trifocal Symposium and "Trifocal Wisdom Hall"Two Core Events, Gathering15 Top Ophthalmology Experts, Deeply shared the insights of Cloudbreak Pharma.^®The Innovative Technology and Clinical Practice Wisdom of the All-New Generation Trifocal Plus Intraocular Lens.

Innovo Medical

· Mini-probe Endoscopic Ultrasound Introduced at Cangzhou Hospital of Integrated Traditional and Western MedicineTwo Tertiary Hospitals in Guizhou

Recently, the "Neptune" mini-probe endoscopic ultrasound developed by InnovaMed was successfully installed at the Endoscopy Center of Cangzhou Hospital of Integrated Traditional and Western Medicine. The introduction of this advanced equipment greatly enriches the department's diagnostic and treatment methods, allowing doctors to handle complex and difficult digestive system diseases with more ease, thereby significantly improving diagnostic and treatment efficiency and success rates.

Two Major Regional Medical Centers in Guizhou — Zunyi First People's Hospital and Anshun People's Hospital — Have Introduced the "Uranus" and "Gemini" Mini-Probe Endoscopic Ultrasound Systems from Yingtai Bio, Empowering Precision Diagnosis and Treatment with Innovative Technology, Allowing Local Residents to Access High-Quality Medical Services Close to Home.

·

The Two Major Regional Medical Centers in the State — Zunyi First People's Hospital and Anshun People's Hospital — Have Recently Introduced the "Uranus" and "Gemini" Mini-Probe Endoscopic Ultrasound Systems from Yingtai.Empower precise diagnosis and treatment with innovative technologies, enabling people to access high-level medical services "at their doorstep."

中美双和

· US-China Double Harmony Peripheral Balloon Successfully Entered and Won Bid in Hebei's "Provincial Alliance Centralized Volume Purchase of Vascular Interventional Medical Consumables"

Recently,US-China Shuanghe Peripheral Balloon Successfully Entered and Won the Bid in Hebei's "Provincial Alliance Centralized Volume Purchase of Vascular Interventional Medical Consumables."

Recently,As a core force, Weimai Medical participated in the "Force Sensing and Force Feedback for Surgical Robots" project under the National Key R&D Program of China's "Intelligent Robots" initiative.This marks that Weimai Medical's innovative strength and technical responsibility in the field of interventional surgical robots have gained authoritative recognition from the highest-level national scientific research plan, deeply integrating into China's strategic layout to break through the "bottleneck" technology of high-end medical equipment.

· Interventional Robot Hands Out the "Made in China" Business Card to the World

On July 24th-25th, the plenary session of the Boao Forum for Asia Global Health Forum Beijing Conference 2025 was held. As an outstanding representative of medical robotics companies, Weimai Medical attended the exhibition with its We RobotDSA·Interventional Robot, showcasing the era's essence of "Made in China" through its cutting-edge technological strength.

Trinomab

· Published in the prestigious international journal "Nature Medicine" (IF=50.0)

On July 8, the Phase III clinical trial results of Trinomab's globally pioneering anti-tetanus toxin monoclonal antibody new drug - Stedutamab Injection (trade name: Xintituo) were published in the international top journal *Nature Medicine* (Impact Factor IF=50.0).

HaploX

· HaploX EMQN-DNA Sequencing-NGS Passes with Full Marks!

Recently, the European Molecular Genetics Quality Network (EMQN)The results of the 2024 DNA SEQUENCING-NGS (Somatic SNVs and indels + matched germline sample) external quality assessment have been announced. HaploX achieved a perfect score in this assessment, marking another comprehensive recognition by EMQN of HaploX's laboratory technical management standards. This indicates that HaploX’s diagnostic quality and standards remain at the forefront of the international stage and have gained recognition from authoritative global institutions.

Kaisi Biotech

· Globalization Strategy Implemented, Factories in the U.S. and Japan Commence Production Simultaneously!

Amid the accelerating restructuring of the globalized CDMO industry, Kaishi Biotech has made a "double-barreled" move – strategically acquiring a controlling stake in NPS, a subsidiary of Japan's PSS Group with 40 years of CDMO history. Starting from July 1, Kaishi Biotech officially took over the management rights of NPS in Japan. Simultaneously, its U.S. consumables production base has commenced operations. This strategic layout not only signifies the deep advancement of Kaishi Biotech's globalization strategy but also injects certainty into the global pharmaceutical industry chain through a "technology + capacity" dual-engine approach, reshaping the industry’s value map. Kaishi Biotech has now officially embarked on a new chapter of globalization with a "dual-core driven" supply chain.

Beimai Pharmaceuticals

· Beimai Pharmaceuticals' Dermatology Product TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) Receives Drug Registration Clinical Trial Application Acceptance Notice

On July 22, Beimai Pharmaceuticals announced that TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) had received the acceptance notice for clinical trial application from the National Medical Products Administration.

Coreach

· CoreEase RuiYuan® DiaSphere® Embolic Microspheres Pre-Market RCT Study Published in Authoritative Journal, Ushering in a New Era of Evidence-Based Embolization Therapy

Recently,Coreach Medical's Self-developed Ruiyuan^®DiaSphere^®Embolic Microspheres Reach Another Milestone Recently——The results of its pre-market randomized controlled trial (RCT) were published online in an authoritative journal. As the first in ChinaEmbolic microspheres for pre-market RCT clinical studies,Rui Yuan^®DiaSphere^®Validating the safety and efficacy of the product according to the gold standard of evidence-based medicine, it fills the gap in pre-market randomized controlled trials (RCT) for high-end medical devices in China's embolization interventional field, providing substantial evidence-based support for its clinical practice.

Xuanyu Medical

· MultipleHospital Performs First Batch of XuanYu RhythPulse® PFA Surgeries

Recently, the cardiology team of the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) successfully applied the unique "Large Loop Modeling·Small Loop Ablation" strategy using China-produced innovative equipment — the RhythPulse® Pulsed Field Ablation (PFA) system — as one of the first in China. They carried out precise and efficient "heart" procedures for two patients with atrial fibrillation!

Shanghai Jiao Tong University School of Medicine AffiliatedThe Cardiology Department of the Sixth People's Hospital Lingang Campus is fully staffed and closely coordinated, and is among the first in China to carry out the Xuan Yu RhythPulse procedure.^®Pulsed Field Ablation (PFA) Surgery.

Director Li Ruogu's team from the Department of Cardiology, Shanghai Chest Hospital,Successfully Completed the First Batch of RhythPulse Medical Devices Produced in China Nationwide^®Pulsed Field Ablation (PFA) Surgery。

Xuyi County People's HospitalCardiologyPoissonDirector successfully appliedXuanyu Medical RhythPulse® Pulsed Field Ablation Catheter, performed for a patient with atrial fibrillationOne-stop Surgery Combining Atrial Fibrillation Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure, which are the first batch of RhythPulse pulse ablation surgeries in China.

· CAFS2025 Xuan Yu Medical PFA System Launch Conference Successfully Held

Recently,The 2ndDuring the 3rd Atrial Fibrillation Academic Conference (CAFS2025), Xuan Yu MedicalShineRhythm® & RhythPulse® Cardiac Pulsed Field Ablation SystemThe listing meeting was successfully held in Dalian, China.

Nolwen Biotech

· Electrochemical Catalysis NO Device Assists in Postoperative Management of Adult Congenital Heart Disease

Recently,Cardiovascular Surgery Team of Peking University International Hospital UsesNoliving Bioelectrochemical Catalysis Nitric Oxide Therapeutic Device (INOwill N200)Clinical research paper on the treatment of pulmonary hypertension associated with congenital heart disease in adults (CHD-PAH), titled "Innovative nitric oxide delivery technology for postoperative pulmonary hypertension in congenital heart disease patients: a clinical trial," has been officially published in the journal BMC Cardiovascular Disorders (Chinese Academy of Sciences SCI Zone 3).

Hannuo Medical

· Hannuo Medical AppearsAPELSO 2025

From July 10 to 12, the 7th Asia-Pacific Extracorporeal Life Support Organization Annual Meeting (APELSO 2025) was held in Beijing, co-organized by the Chinese Society of Biomedical Engineering, the Extracorporeal Circulation Branch of the Chinese Society of Biomedical Engineering, and the Asia-Pacific Extracorporeal Life Support Organization. Leveraging the APELSO as an international authoritative academic platform, Hannover Medical systematically showcased its significant progress in product innovation to experts, scholars, and industry peers in the Asia-Pacific region. This includes: continuous upgrades in device performance — through optimizing hemodynamic management accuracy and extending the stable operation time of equipment; enhanced convenience and safety in clinical applications — relying on intelligent human-machine interaction interfaces and comprehensive monitoring systems; as well as ongoing efforts and breakthrough improvements in portable transport solutions.

· Lifemotion® ECMO Centrifugal Pump Recognized by International Authoritative Journal

Recently, the research findings published in the international authoritative journal "ASAIO Journal," titled "Hemolysis in a Novel Centrifugal Blood Pump With Low Priming Volume: In Vitro Comparative Study Using Human Blood and Numerical Analysis," scientifically validated this issue. The study shows that Hannuo Medical's Lifemotion® centrifugal pump not only reduces the size of the centrifugal pump but also decreases the area of high shear stress regions within the pump, demonstrating excellent hemodynamic performance and reducing the risk of hemolysis compared to similar blood pumps.

Kaituo Biotech

· Founder of Cadence Biotech Appointed as Entrepreneurship Mentor at Suzhou Biomedical Sub-Center, Empowering the Ecosystem through the CRDMO Platform

Recently, the BioMatch Overseas Talent Session, hosted by the Regional Technology Transfer and Transformation Center for Biomedicine of Universities across China (Suzhou, Jiangsu) (hereinafter referred to as "Suzhou Biomedicine Sub-center"), was held in Suzhou Industrial Park. Dr. Ren Keyun, General Manager of Cytoscape Biotech, was invited to be appointed as the "Entrepreneurship Mentor" of the Suzhou Biomedicine Sub-center. Together with experts from top institutions such as the Hong Kong Polytechnic University and the Suzhou Research Institute of the National University of Singapore, they formed a "think tank" to provide precise guidance for the transformation of biomedicine achievements.

Reindeer Bio

· Caribou Biosciences' Ixazomifene Injection (Fucaso) Receives Orphan Drug Designation from South Korea's Ministry of Food and Drug Safety

On July 9, Icarus Bio announced that the South Korean Ministry of Food and Drug Safety (MFDS) granted Orphan Drug Designation (ODD) to its self-developed BCMA-targeted CAR-T cell therapy product, Fucaso (Idecabtagene Vicleucel) Injection, for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have experienced disease progression after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent).

Tianqin Biotech

· Building a One-Stop New Drug R&D Platform from Target to IND

Recently, Tianqin Biotech and ChemPartner Corporation officially signed a strategic cooperation agreement. This collaboration aims to deeply integrate the core advantages of both parties in the innovative drug R&D industry chain, jointly creating a one-stop service platform covering the entire process "from target discovery to IND," providing global pharmaceutical companies with more efficient and professional solutions.

Senmai Medical

· Taking the Lead in Global Collaboration to Build a New Blueprint for Intelligent Drug Delivery

Recently,The World-Focused Pharmaceutical EventCPHI China 2025 Successfully concluded.Senmai Medical Technology and International Pharmaceutical PackagingBrandNanjingBaTevfik and Flexcon Join Hands, Sign Strategic Cooperation Agreement, and Embark on a New Journey of Global Innovation and Industrial Application of Drug Delivery Devices.This timeCooperation Focuses on Specialized Packaging andLevel IIThe development of pharmaceutical packaging materials is dedicated to providing customers with better overall solutions to achieve the integration of drugs and devices.Bringing New Breakthroughs to the Medical Industry.

Microchip Biotech

· Milestone in First-Line DLBCL Treatment! Final Top-Line Analysis of Chidamide DEB Study Achieves Primary Endpoint of EFS

Recently, the pivotal Phase III clinical trial (DEB study) of Chidamide, a globally first-in-class optimal drug independently developed by Chipscreen Biosciences, for the treatment of diffuse large B-cell lymphoma (DLBCL) in combination with frontline therapy and as a single-agent maintenance therapy, has completed the final top-line analysis. The results showed that the event-free survival (EFS) of the experimental group was significantly better than that of the control group, achieving the primary endpoint of the study.

Ascentage Pharma

· China's First Domestically Developed Bcl-2 Inhibitor, Lisentux®, Prescribed for the First Time

On July 25, Ascentage Pharma announced that the first domestically produced original Bcl-2 inhibitor in China, Lisentux® (generic name: lisauxoclax; research code: APG-2575), has been prescribed for the first time in multiple locations across China today and officially began supplying in various provinces and cities.

· Ascentage Pharma Partners with Leading Pharmaceutical Distribution Companies to Advance the Commercialization of Lisondra®

Recently,Ascentage Pharma announced that the company has signed cooperation agreements with Sinopharm Group Co., Ltd. ("Sinopharm"), Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharma"), and China Resources Tianjin Pharmaceutical Co., Ltd. ("China Resources Tianjin") respectively. This collaboration aims to leverage the strengths of both parties in R&D innovation, market expansion, and channel management to jointly advance the first domestically produced original Bcl-2 inhibitor, Lishengtuo, which has been approved for marketing.^®(General Name: Lisactopril) Commercialization Process.

Healthgen Biotech

· The authoritative international journal of hepatology, *Gut*, published a commentary on the significant clinical implications of Aofumin® in albumin therapy.

Recently,The official journal of the British Society of Gastroenterology:Gut》(Impact Factor 25.8) published a special commentary jointly written by Professor Rajiv Jalan from University College London and Professor Paolo Caraceni from the University of Bologna, focusing on the recombinant human albumin expressed in rice endosperm (Oufumin) developed by a Chinese team.^®）ofⅡIn-depth analysis of clinical research in the period. The review is titled ""New Frontier in Albumin Replacement Therapy" Highlights Innovative Treatment That May Reshape the Landscape of Albumin Therapy for Patients with Liver Cirrhosis.

Cloudbreak Pharma

· CBT-004 Phase II Clinical Trial for the Treatment of Vascularized Pterygium Shows Positive Results

Recently, Cloudbreak Pharma announced its evaluationCBT-004Positive Topline Results Announced from Phase II Clinical Trial of Ophthalmic Solution for Vascularized Pinguecula and Related Conjunctival Hyperemia.

Key Results of Phase II Clinical Trials:

Achieve the primary endpoint：The independent imaging center showed through digital imaging evaluation that, in the28Days, two test concentrations ofCBT-004Compared with the solvent control group, conjunctival congestion was significantly improved in a statistically significant manner.

Rapid onset and long-lasting efficacy:The highest concentration testedCBT-004As early as the7Significant improvement was observed in days, and the benefits lasted throughout the entire period.28Days of treatment.

Significant relief of symptoms:Two concentrations ofCBT-004In the patient reports5A common symptom (including burning/Stinging, itching, foreign body sensation, ocular discomfort, and pain all showed statistically significant improvement, superior to the vehicle control group.

Excellent Safety:No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically significant changes in vision or intraocular pressure were reported.

Xuanzhu Biotech

· Piroxelisib Tablets (Xuanyuenning®) Launched Nationwide in China, Opening a New Era in the Treatment of Advanced HR+/HER2- Breast Cancer

Recently, the first batch of commercial products of Xuanzhu Biotech's self-developed Class 1 innovative drug, Piroxelisib Tablets (Xuanyuenin®), has successfully completed production packaging and quality release at Asymchem Group. This marks the official entry into the commercial supply phase for this strategic innovative drug, which is included in the "National Key R&D Program for New Drug Creation during the 13th Five-Year Plan." As a significant breakthrough in China’s breast cancer treatment field, this drug will provide better treatment options for patients with HR+HER2- advanced breast cancer.

· The First Prescriptions of Pyrotinib Tablets (Xuanyuenning®) Have Been Issued, Successfully Filling the Treatment Gap for Late-line Monotherapy in Advanced HR+/HER2- Breast Cancer in China

Recently，Xuanzhu Biotech's Class 1 innovative drug — Piroxelisib Tablets (Xuanyuenning)^®), as the first and currently only CDK4/6 inhibitor in China for monotherapy in HR+/HER2- breast cancer treatment, has now completed its initial nationwide drug supply, with the first prescriptions already issued at multiple hospitals for clinical treatment. This marks a new era of "high efficacy, low toxicity, and single-agent breakthrough" in the treatment of advanced breast cancer in China, offering a new therapeutic option for breast cancer patients.

· New Generation PPI AnlazolSodium Enteric-Coated Tablets Complete First Patient Enrollment in Phase III Clinical Study for Reflux Esophagitis

On July 30, the Phase III clinical study (CTR20252165) for the treatment of reflux esophagitis with Anaila Sodium Enteric-coated Tablets, a Class 1 new drug independently developed by Xuanzhu Biotech, completed the enrollment of the first subject at the Second Affiliated Hospital of Wenzhou Medical University. This marks a significant milestone in the development progress of Anaila Sodium, moving one step closer to providing a better treatment option for the large population of patients with reflux esophagitis in China.

Frontier Biotech

· Research Results of Aikening® 4-Week Regimen Combined with Dolutegravir Presented at the 13th IAS Conference on HIV Science

On July 13, the 13th IAS Conference on HIV Science (IAS 2025) was grandly opened in Kigali, Rwanda. Frontier Biotech showcased two innovative research achievements of Aikening® (generic name: Albuvirtide) with a 4-week dosing regimen combined with Dolutegravir, presenting the "Chinese solution" for long-acting HIV treatment to the world in poster form.